Terms: = Lung cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
367 results:
1. Disease control in patients with non-small cell lung cancer using pemetrexed: Investigating the best treatment strategy.
Takahara Y; Abe R; Sumito N; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
Thorac Cancer; 2024 Apr; 15(12):987-993. PubMed ID: 38485287
[TBL] [Abstract] [Full Text] [Related]
2. Association of Nutritional Indices With Adverse Effects and Time-to-treatment-Failure in Triple Therapy for lung cancer.
Hashino Y; Matushita T; Hatsuyama T; Wakamoto A; Goto K; Hoshi T; Iwayama K; Ohtaki K; Toda T; Sato H
In Vivo; 2024; 38(2):864-872. PubMed ID: 38418111
[TBL] [Abstract] [Full Text] [Related]
3. Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Akita T; Ariyasu R; Kakuto S; Miyadera K; Kiritani A; Tsugitomi R; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Tasaka S; Nishio M
Thorac Cancer; 2024 Apr; 15(10):788-796. PubMed ID: 38400801
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
Chen J; Zheng Q; Wang J; Zhang X; Lv Y
Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
[TBL] [Abstract] [Full Text] [Related]
5. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
6. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
Cheng WC; Lin CC; Liao WC; Lin YC; Chen CH; Chen HJ; Tu CY; Hsia TC
BMC Cancer; 2024 Feb; 24(1):228. PubMed ID: 38373960
[TBL] [Abstract] [Full Text] [Related]
7. Influence of
Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
[TBL] [Abstract] [Full Text] [Related]
8. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
Pham CP; Nguyen TTH; Do AT; Nguyen TK; Hoang TAT; Le TA; Vuong DTH; Nguyen DNT; Dang VK; Nguyen TO; Pham VL; Nguyen MH; Vo THT; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Nguyen KD; Nguyen HG; Truong CM; Pham TMC; Nguyen TBP
BMC Cancer; 2024 Feb; 24(1):176. PubMed ID: 38317094
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract] [Full Text] [Related]
10. "All in one" nanoprobe Au-ttf-1 for target FL/CT bioimaging, machine learning technology and imaging-guided photothermal therapy against lung adenocarcinoma.
Yang Z; Zhang Y; Tang L; Yang X; Song L; Shen C; Zvyagin AV; Li Y; Yang B; Lin Q
J Nanobiotechnology; 2024 Jan; 22(1):22. PubMed ID: 38184620
[TBL] [Abstract] [Full Text] [Related]
11. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
[TBL] [Abstract] [Full Text] [Related]
12. Association of Geriatric Nutritional Risk Index With Immune Checkpoint Inhibitor treatment Duration and Adverse Events in lung cancer.
Shimizu A; Fukasawa M; Mitani K; Goto K; Wakamoto A; Hatsuyama T; Hoshi T; Hasegawa I; Sato H
In Vivo; 2024; 38(1):418-424. PubMed ID: 38148096
[TBL] [Abstract] [Full Text] [Related]
13. Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell lung cancer: A Real-World Population Study.
Lim CA; Ghosh S; Morrison H; Meyers D; Stukalin I; Kerba M; Hao D; Pabani A
Curr Oncol; 2023 Dec; 30(12):10396-10407. PubMed ID: 38132391
[TBL] [Abstract] [Full Text] [Related]
14. Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants.
Ohishi Y; Nakanishi Y; Hirotani Y; Suzuki A; Tanino T; Nishimaki-Watanabe H; Kobayashi H; Nozaki F; Ohni S; Tang X; Hayashi K; Nakagawa Y; Shimizu T; Tsujino I; Takahashi N; Gon Y; Masuda S
Thorac Cancer; 2024 Jan; 15(1):89-93. PubMed ID: 38093515
[TBL] [Abstract] [Full Text] [Related]
15. Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.
Xie S; Fang Y; Yang Y; Liu L; Bai J; Lin S; Zhang B; Fang Y
Eur J Pediatr; 2024 Feb; 183(2):557-567. PubMed ID: 38019286
[TBL] [Abstract] [Full Text] [Related]
16. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y; Saito G; Sakata S; Oya Y; Tamiya M; Suzuki H; Shibaki R; Okada A; Yokoyama T; Matsumoto H; Otsuki T; Sato Y; Junji U; Tsukita Y; Inaba M; Ikeda H; Arai D; Maruyama H; Hara S; Tsumura S; Morinaga J; Sakagami T
Lung Cancer; 2023 Dec; 186():107426. PubMed ID: 37992594
[TBL] [Abstract] [Full Text] [Related]
17. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
[TBL] [Abstract] [Full Text] [Related]
18. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
Masuda T; Miura S; Sato Y; Tachihara M; Bessho A; Nakamura A; Miyawaki T; Yoshimine K; Mori M; Shiraishi H; Hamai K; Haratani K; Maeda S; Tabata E; Kitagawa C; Tanizaki J; Imai T; Nogami S; Yamamoto N; Nakagawa K; Hattori N
Sci Rep; 2023 Nov; 13(1):19729. PubMed ID: 37957228
[TBL] [Abstract] [Full Text] [Related]
19. Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective study.
Jin J; Visina J; Burns TF; Diergaarde B; Stabile LP
Sci Rep; 2023 Oct; 13(1):17047. PubMed ID: 37813923
[TBL] [Abstract] [Full Text] [Related]
20. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma.
Wang K; Liu X; Ding Y; Sun S; Li J; Geng H; Xu M; Wang M; Li X; Sun D
BMC Pulm Med; 2023 Oct; 23(1):377. PubMed ID: 37805451
[TBL] [Abstract] [Full Text] [Related]
[Next]
